ArticleExperimental physiology2026
Humanin ameliorates diabetes-induced testicular damage in a streptozotocin-induced mouse model.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Humanin ameliorates diabetes-induced testicular damage in a streptozotocin-induced mouse model.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Diabetes mellitus is a major metabolic disorder closely associated with oxidative stress and male reproductive dysfunction. Humanin, a mitochondria-derived peptide, has been reported to exert cytoprotective, anti-apoptotic and antioxidant effects in various disease models; however, its role in diabetes-induced testicular damage remains unclear. This study aimed to investigate the effects of humanin on oxidative stress parameters in seminal vesicle fluid and histopathological alterations in testicular tissue in a streptozotocin (STZ)-induced diabetic mouse model. A total of 40 adult male Balb/C mice were randomly assigned into four groups: Control, Humanin (HN), STZ, and STZ+HN (n = 10 per group). Diabetes was induced via intraperitoneal administration of STZ (150 mg/kg). Humanin (4 mg/kg) was administered intraperitoneally for 15 days following diabetes induction. Total antioxidant status (TAS), total oxidant status (TOS), and glutathione (GSH) levels in seminal vesicle fluid were measured using ELISA. Testicular tissues were evaluated histopathologically and histomorphometrically. STZ-induced diabetes resulted in a significant decrease in TAS and GSH levels and an increase in TOS levels in seminal vesicle fluid (P < 0.05). Humanin treatment significantly increased TAS and GSH levels while reducing TOS levels compared to the STZ group (P < 0.05). Histopathological analysis demonstrated seminiferous tubule degeneration, germ cell loss, interstitial oedema, and vascular congestion in diabetic mice, whereas these alterations and associated histomorphometric abnormalities were significantly ameliorated following humanin treatment. Humanin attenuated diabetes-induced oxidative imbalance and testicular histopathological damage in STZ-induced diabetic mice. These findings suggest that humanin may exert protective effects against diabetes-associated testicular injury. Further studies are required to elucidate the underlying molecular mechanisms and validate these findings in broader experimental settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.